Empagliflozin in Patients With Glomerulonephritis

Sponsor
Kasr El Aini Hospital
Study ID
NCT05283057
Phase
PHASE3
Status
Completed

Conditions

  • Glomerulonephritis
  • Proteinuria

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin 25 MG — DRUG
    single dose of the SGLT inhibitor Empagliflozin was given
  • placebo — DRUG
    single dose of placebo that is similar to Empagliflozin in physical appearance

Study Details

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are newly developed antihyperglycemic medications. In addition to their glucose lowering properties, they have been shown to have favourable effects on the cardiovascular and renal outcome in patients with diabetes. one of the most interesting renal effects is reduction of proteinuria. The aim of our study was examine the effect of SGLT inhibitors on proteinuria in patients with glomerulonephritis. This study is a randomised controlled trial.

Key Dates

Start date
Feb 20, 2020
Status verified
Mar 2022
Primary completion
Sep 30, 2021
Completion
Sep 30, 2021

Study Design

Enrollment
50 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Group 1: Empagliflozin
    25 patients with glomerulonephritis and proteinuria who were treated with Empagliflozin
  • Placebo Comparator: Group 2:
    25 patients with glomerulonephritis and proteinuria who were treated with standard treatment and placebo

Primary Outcome Measure

protein to creatinine ratio [ Time Frame: 3 months ]

Related Studies